ArticleESMO real world data and digital oncology2025

Health care policies, drug costs, and time toxicities in biologics for HER2-positive breast cancer: cost minimization analysis of direct and indirect costs.

J L Low et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.